Blog | HemaCare

Extracellular Vesicles Boost Grafting Ability in Cells

Aug 20, 2019 10:11:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Bone Marrow, Stem Cells, Blood Disorders

0 Comments

A new study shows that we may be able to boost the grafting ability in cells for people receiving a bone marrow transplant.

Allogenic stem cell transplantation is a treatment approach in people with diseases that are destructive to the bone marrow, such as multiple myeloma, leukemia, and Hodgkin´s lymphoma. The goal is to restore bone marrow after total-body chemotherapy and irradiation. The transplantation procedure involves transferring hematopoietic stem cells from compatible, healthy donors to a patient. An important complication of this procedure is rejection and destruction of the donated stem cells by the recipient’s immune system before engraftment can occur.

Read More

HemaCare Leukopaks Support Novel Gene Editing Strategy

May 7, 2019 10:07:00 AM / by Nancy Andon, MSc posted in Leukopak, Stem Cells, Blood Disorders

0 Comments

In an independent publication [1] researchers at UCLA cited using leukopaks obtained from HemaCare in order to investigate a new gene editing method.

The group is researching strategies to treat genetic blood disorders such as sickle cell anemia. While there has been a great deal of research focused on using CRISPR/Cas9 gene therapy to treat these illnesses [2], current strategies for gene editing in hematopoietic stem cells are inefficient, and thus costly.

Read More

HemaCare Bone Marrow Tissue Boosts Development of Cell Therapy for Sickle Cell Disease

Dec 12, 2018 10:10:00 AM / by Nancy Andon, MSc posted in Bone Marrow, Stem Cell Therapy, Stem Cells, Blood Disorders

0 Comments

An independent study cites the use of HemaCare-sourced human bone marrow-derived CD34+ stem cells for research into a potential new therapy for sickle cell disease. [1]

Sickle cell is a serious disease that affects millions of people throughout the world. People affected by sickle cell anemia have rigid, sickle-shaped red blood cells that can’t adequately carry oxygen to the body’s tissues. As a result, sickle cell patients suffer from a variety of medical complications, which can shorten their life span. Contemporary cell therapy treatments have focused on a gene therapy approach that uses lentiviral vectors to supply CD34+ bone marrow-derived stem cells with an unimpaired version of the hemoglobin gene. While this tactic has met with some promise, finding healthy, matched bone marrow donors is difficult. Researchers at Biogen, a well-known biotech firm headquartered in Cambridge, Massachusetts, are trying to discover cell and gene therapy methods that they hope will provide an alternative solution, and thereby improve treatment success rates.

Read More

Progress in Sickle Cell Cure Research

Mar 26, 2018 10:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in disease-state products, Stem Cells, Blood Disorders

0 Comments

The findings of a new study on sickle cell disease may lead to a new era in the approach to treatment.

Sickle cell disease (often referred to as sickle cell anemia) is a group of blood disorders in which the blood cells have an abnormal sickle shape instead of the biconcave disk shape. The sickle-shaped cells have a shorter life span (leading to anemia), but they also block normal blood flow leading to pain and organ dysfunction. There is no cure, and treatments that exist are aimed to control symptoms and related complications.

Read More

Gene Therapy Tackles Sickle-Cell Disease

Jan 8, 2018 10:25:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Gene Therapy, Blood Disorders

0 Comments

Sickle cell disease (SCD) is a genetic disorder that affects red blood cells. This disease affects people of color more commonly and is due to the effect of abnormally shaped red blood cells (crescent or sickle-shaped instead of disc shaped). The misshapen red blood cells contain a form of hemoglobin, hemoglobin S, resulting from mutation of the beta-globin gene. Hemoglobin S does not hold oxygen efficiently, and the abnormal shape of the red blood cells prevents normal flow through the blood vessels, leading to vessel blockage. This leads to the pain and tissue damage seen in patients with SCD.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts